Pharmafile Logo
Pharmafocus logo
Advanced Search

Gazyvaro

Showing 7 posts of 7 posts found.

NICE backtracks to recommend Roche’s Gazyvaro in follicular lymphoma

February 12, 2018
Sales and Marketing Gazyvaro, NHS, NICE, Roche, follicular lymphoma

Roche has announced that NICE has issued its final decision to recommend the use of its Gazyvaro (obinutuzumab). The glyco-engineered …

News
roche

Roche secures EU approval for Gazyvaro in new lymphoma indication

June 16, 2016
Research and Development, Sales and Marketing EU, Gazyvaro, Roche, follicular lymphoma

Roche (SIX: RO) has announced that the European Commission has approved Gazyvaro (obinutuzumab), in combination with bendamustine chemotherapy, in patients …

News
Roche logo

NICE signs-off Roche’s Gazyvaro for leukaemia

June 2, 2015
Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia

NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …

News

NICE approves Roche’s Gazyvaro and Novartis’ Xolair

March 11, 2015
Research and Development, Sales and Marketing Gazyvaro, NICE, Novartis, Roche, Xolair, obinutuzumab, omalizumab

NICE today gave the green light to three new biological drugs, after recommending Roche’s Gazyvaro, GSK’s Arzerra and Novartis’ Xolair …

News

Roche wins drug discovery award for Gazyvaro

December 18, 2014
Sales and Marketing BPS, British Pharmacological Society, GSK, Gazyvaro, Roche, mekinist

Roche has been named the winner of the 2015 Drug Discover of the Year award by the British Pharmacological Society …

News
Roche image

NICE U-turn on Roche leukaemia drug

December 2, 2014
Sales and Marketing Gazyvaro, MabThera, NHS, NICE, Roche, leukaemia, obinutuzumab

NICE has reversed its decision on Roche’s chronic lymphocytic leukaemia (CLL) drug Gazyvaro only two months after rejecting the drug. …

News
Roche image

Roche falls foul of NICE rules, again

October 3, 2014
Medical Communications, Sales and Marketing CLL, Gazyvaro, NICE, Roche, blood cancer, oncology

Uncertainties in the data and high cost have seen NICE make an initial rejection of Roche’s new blood cancer drug …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025